Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Current Quarter	$-0.45	Next Quarter	$-0.37
Current Year	$-2.2	Next Year	$-1.93
QoQ Growth	+17.8%	YoY Growth	+12.3%
3Y EPS CAGR	-31.6%	Target Price	$16.33
Consensus	Buy	Upside	+574.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VERU	$2.42	-5.47%	97.16K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VERU	$2.42	-5.5%	97.16K
3
4
5
6

VERU

VERU

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Veru Inc. Data in Excel

Get Veru Inc. Data in Excel